問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University Hospital (在職)

Division of Pediatrics

Division of Hematology & Oncology

更新時間：2023-09-19

劉彥麟Liu, Yen-Lin
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

Recruiting Trial

12Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

劉彥麟

List

17Cases

2019-10-30 - 2027-10-27

Phase III

ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX

  • Condition/Disease

    Acquired hemophilia

  • Test Drug

    Fitusiran

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting3Sites

Terminated3Sites

2019-06-14 - 2021-11-30

Phase III

ATLAS-PPX: an open-label, multinational, switching study to describe the efficacy and safety of fitusiran prophylaxis in patients with hemophilia A and B previously receiving factor or bypassing agent prophylaxis.

  • Condition/Disease

    Acquired hemophilia

  • Test Drug

    Fitusiran

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

2018-03-01 - 2020-05-31

Phase III

ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX

  • Condition/Disease

    Hemophilia A or B

  • Test Drug

    Fitusiran (ALN-AT3SC)

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

張家堯
Taipei Medical University Hospital

Division of Pediatrics

2020-01-01 - 2026-12-31

Phase I/II

A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations

  • Condition/Disease

    Advanced or metastatic malignancies

  • Test Drug

    Repotrectinib

Participate Sites
2Sites

Recruiting2Sites

2022-04-01 - 2025-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2018-03-01 - 2022-08-31

Phase III

A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTICENTER, CONTROLLED TRIAL TO EVALUATE THE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN AND TO COMPARE THE EFFICACY AND SAFETY OF EDOXABAN WITH STANDARD OF CARE ANTICOAGULANT THERAPY IN PEDIATRIC SUBJECTS FROM BIRTH TO LESS THAN 18 YEARS OF AGE WITH CONFIRMED VENOUS THROMBOEMBOLISM (VTE)

  • Condition/Disease

    Venous thromboembolism

  • Test Drug

    Edoxaban

Participate Sites
5Sites

Recruiting5Sites

2018-05-15 - 2021-06-11

Phase II

Multiple escalating dose study of BAY 1093884 in adults with hemophilia A or B with or without inhibitors

  • Condition/Disease

    hemophilia A or B

  • Test Drug

    BAY 1093884

Participate Sites
6Sites

Terminated5Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB